Date: November 21, 2026

Regulatory Disclosure Summary

NATCO Pharma Limited has disclosed the conclusion of a U.S. Food and Drug Administration (USFDA) inspection at its formulation manufacturing facility located in Kothur, Hyderabad, India.

Inspection Details

The USFDA inspection was conducted from November 12th to November 20th, 2026, at the company's formulation manufacturing plant in Kothur, Hyderabad.

Inspection Outcome

Upon conclusion of the inspection, the company received seven (7) observations documented in Form-483. The company has characterized these observations as "procedural in nature" and expressed confidence in its ability to address these observations comprehensively within the stipulated timelines required by regulatory authorities.

Company Background

NATCO Pharma Limited develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The company is R&D oriented and a science-driven leading Oncology player in targeted therapies. The company's manufacturing facilities are approved by several leading regulatory authorities including US FDA, Brazil ANVISA, Health Canada, and WHO, catering to 50+ global markets.